Bristol Myers Squibb (BMS) has disclosed positive data from two pivotal trials for its drug, Sotkytu, in treating psoriatic arthritis. The results could help expand the use of the drug, which is a TYK2 inhibitor, beyond its current approval for treating plaque psoriasis. This could boost the product’s revenue and offer patients an alternative treatment option. The company plans to share detailed results at future medical conferences.
iOS devices more exposed to phishing than Android
Cybercrime groups are increasingly targeting mobile devices, with a 32% jump in malicious app detections and a 17% increase in enterprise-focused credential theft and phishing
